Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)
Trial · NCT04333147
Results by group323
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 323
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) | Otilimab 90 mg | Participants with AEs | 902 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) | Otilimab 150 mg | Participants with AEs | 931 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) | Otilimab 90 mg | Participants with SAEs | 123 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) | Otilimab 150 mg | Participants with SAEs | 114 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) | Otilimab 90 mg | Participants with AESI | 120 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) | Otilimab 150 mg | Participants with AESI | 95 | Participants | |
| Change From Baseline in Hematology Parameter of Platelet Count at Week 24 | Otilimab 90 mg | -11.9 | Standard Deviation 66.86 | Giga cells per liter (10^9 cells/L) | |
| Change From Baseline in Hematology Parameter of Platelet Count at Week 24 | Otilimab 150 mg | -9.7 | Standard Deviation 66.82 | Giga cells per liter (10^9 cells/L) | |
| Change From Baseline in Hematology Parameter of Platelet Count at Week 48 | Otilimab 90 mg | -12.5 | Standard Deviation 66.47 | Giga cells per liter (10^9 cells/L) | |
| Change From Baseline in Hematology Parameter of Platelet Count at Week 48 | Otilimab 150 mg | -7.6 | Standard Deviation 71.36 | Giga cells per liter (10^9 cells/L) | |
| Change From Baseline in Hematology Parameter of Platelet Count at Week 96 | Otilimab 90 mg | -13.8 | Standard Deviation 60.72 | Giga cells per liter (10^9 cells/L) | |
| Change From Baseline in Hematology Parameter of Platelet Count at Week 96 | Otilimab 150 mg | -5.7 | Standard Deviation 72.81 | Giga cells per liter (10^9 cells/L) | |
| Change From Baseline in Hematology Parameter of Platelet Count at Week 144 | Otilimab 90 mg | 17.0 | Standard Deviation NA | Giga cells per liter (10^9 cells/L) | |
| Change From Baseline in Hematology Parameter of Platelet Count at Week 144 | Otilimab 150 mg | -37.5 | Standard Deviation 40.31 | Giga cells per liter (10^9 cells/L) | |
| Change From Baseline in Hematology Parameter of Hemoglobin at Week 24 | Otilimab 90 mg | 0.4 | Standard Deviation 10.10 | Gram Per Liter (g/L) | |
| Change From Baseline in Hematology Parameter of Hemoglobin at Week 24 | Otilimab 150 mg | 0.3 | Standard Deviation 9.89 | Gram Per Liter (g/L) | |
| Change From Baseline in Hematology Parameter of Hemoglobin at Week 48 | Otilimab 90 mg | -0.5 | Standard Deviation 10.38 | Gram Per Liter (g/L) | |
| Change From Baseline in Hematology Parameter of Hemoglobin at Week 48 | Otilimab 150 mg | -1.1 | Standard Deviation 10.62 | Gram Per Liter (g/L) | |
| Change From Baseline in Hematology Parameter of Hemoglobin at Week 96 | Otilimab 90 mg | 1.0 | Standard Deviation 11.37 | Gram Per Liter (g/L) | |
| Change From Baseline in Hematology Parameter of Hemoglobin at Week 96 | Otilimab 150 mg | 1.2 | Standard Deviation 10.24 | Gram Per Liter (g/L) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04333147/results